Zydus Lifesciences on Wednesday reported a 11.7 decline in its consolidated net profit in the April to June quarter of this fiscal year, on account of lower domestic sales.
However, the company's net profit of Rs 518.3 crore was 4.8 percent higher than the Street estimate of Rs 494.6 crore.
It also reported a 1.2 percent rise in income at Rs 4,072.7 crore from last year's Rs 4,025.4 crore. The company's revenue was also very close to the CNBC-TV18 poll prediction of Rs 4,048 crore.
"We are encouraged by our stable Q1 FY23 performance, particularly with the rebound in US business even as consumer wellness and emerging markets sustained growth momentum," Sharvil Patel, the Zydus Lifesciences Managing Director, said.
India branded formulations business, adjusting for COVID impact delivered healthy growth, he added.
However, the company reported a 10.7 percent decline in its earnings before interest, taxes, depreciation, and amortization (EBITDA) at Rs 833 crore, compared to the same period last year. It was also 2.4 percent lower than Street estimate.
The company reported a 20.4 percent EBITDA margin, 70 bps lower than the Street estimate and 280 bps lower than last year's 23.2 percent.
With PTI inputs
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Every student suicide pains me, I will try better: BJP Kota MP Om Birla
Apr 16, 2024 2:19 PM
Bihar Lok Sabha elections 2024: Schedule, total seats, Congress candidates and more
Apr 16, 2024 1:02 PM
Lok Sabha polls: BJP drops Som Parkash, fields Abhijit Das against Mamata's nephew
Apr 16, 2024 12:49 PM